Department of Pediatrics and Neonatology, National Children's Medical Center; the Laboratory of Neonatal Diseases, National Commission of Health, Children's Hospital of Fudan University, Shanghai, China.
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California.
J Appl Physiol (1985). 2021 Jul 1;131(1):220-228. doi: 10.1152/japplphysiol.00027.2021. Epub 2021 May 6.
Eligibility of ventilated preterm rabbit model to investigate extreme pulmonary immaturity at birth transition is unknown. By extending this model to early saccular stage of fetal lung development, we evaluated efficacy in survival, lung maturation, and underlying mechanisms of contemporary perinatal therapies. Pregnant New Zealand White rabbit does were given dexamethasone (DEX), or sham injection as control (NDEX), 48 and 24 h before delivery at gestational age (GA) of 25-28 days. At birth, newborn rabbits were anesthetized and randomly allocated to four groups receiving either surfactant or nonsurfactant for both DEX and NDEX, and mechanically ventilated within low tidal volumes. Ranges of time to maintain survival rate ≥ 50% in GA 25-28 days were 59-136, 138-259, 173-288, and 437 to ≥600 min, respectively, each across the four groups. The benefits of DEX and/or surfactant for survival were more obvious in GA 25-26 days, as judged by improved lung mechanics, lower lung injury scores, higher lung surfactant phospholipid pools, and surfactant protein mRNA expression, with DEX-surfactant combination being the most optimal for the outcome. In contrast, those of GA 27-28 days had variable but meaningful responses to the treatment. Cox regression analysis revealed GA, DEX, and surfactant being independently protective factors whereas pneumothorax was a risk factor. The extremely preterm rabbits at GA 25-26 days markedly responded to the perinatal therapies for longer survival, lung maturation and injury alleviation, and were relevant for study of preterm birth transition-associated morbidities and underlying mechanisms. An extremely preterm rabbit model with gestational age of 25-26 () days was established by mechanical ventilation with individually adjusted tidal volume at lower ranges. The administration of antenatal glucocorticoids and/or postnatal surfactant achieved significantly longer duration to maintain 50% survival and facilitated lung maturation and protection at early saccular stage. The usefulness of this model should be validated in future investigation of perinatal and neonatal morbidity and mortality at extremely preterm birth transition.
通气早产儿兔模型是否适合研究出生过渡期的极度肺不成熟尚不清楚。通过将该模型扩展到胎儿肺发育的早期囊泡阶段,我们评估了当代围产治疗的疗效、肺成熟度和潜在机制。在妊娠 25-28 天的胎龄 (GA) 前 48 和 24 小时,给予新西兰白兔妊娠兔地塞米松 (DEX) 或假注射对照 (NDEX)。出生时,新生兔麻醉后随机分为四组,分别给予 DEX 和 NDEX 表面活性剂或非表面活性剂,并在低潮气量下机械通气。GA 25-28 天内维持存活率≥50%的时间范围分别为 59-136、138-259、173-288 和 437 至≥600 分钟,每组跨越 4 组。DEX 和/或表面活性剂对存活率的益处在 GA 25-26 天更为明显,表现为肺力学改善、肺损伤评分降低、肺表面活性物质磷脂池升高和表面活性蛋白 mRNA 表达升高,DEX-表面活性剂联合治疗效果最佳。相比之下,GA 27-28 天的治疗效果则存在不同程度但有意义的反应。Cox 回归分析显示 GA、DEX 和表面活性剂是独立的保护因素,而气胸是危险因素。GA 25-26 天的极早产儿对围产期治疗反应明显,存活时间更长,肺成熟度和损伤减轻,与研究早产相关并发症和潜在机制相关。通过在较低范围内调整个体化潮气量的机械通气,建立了胎龄为 25-26 天的极早产儿兔模型。产前糖皮质激素和/或产后表面活性剂的给药显著延长了维持 50%存活率的时间,并促进了早期囊泡阶段的肺成熟和保护。该模型的有用性应在未来对极早产出生过渡相关围产和新生儿发病率和死亡率的研究中进行验证。